The company held an interim general meeting of shareholders
Release time:
2020-11-23
to elect a new board of directors and the board of supervisors
to appoint a new management team
. on November 17, the on-site meeting of the first interim shareholders' meeting of Jianfeng group in 2020 was successfully held, deliberating and passing the proposal on the general election of the board of directors and the proposal on the general election of the board of supervisors, and electing a new board of the board of directors and the board of supervisors, appoint a new management team.
This meeting was convened by the board of directors of the group company and presided over by Chairman Jiang Xiaomeng. Company directors, supervisors and the secretary of the board of directors to attend the meeting, senior management personnel to attend the meeting. A total of 127 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 64,843,258, accounting for 18.8451 of the total number of voting shares of the company. The meeting adopted a combination of on-site voting and online voting to elect Jiang Xiaomeng, Yu Jianhong, Liu Bo, Zhang Guoping, Huang Sujian, Huang Jinlong, Fu Qi (female), Shen Weiguo and Yang Dalong as directors of the 11th board of directors of the company, of which Fu Qi, Shen Weiguo and Yang Dalong were independent directors; chen Tianci, Lu Ruimei (female), Qin Xuping, Shi Fu and Dai Jinxiao were elected as supervisors of the 10th board of supervisors of the company, of which Qin Xuping and Dai Jinxiao were employee representative supervisors of the company. On the same day, the new board of directors held its first meeting, electing Jiang Xiaomeng as the chairman of the 11th board of directors of the company, appointing Yu Jianhong as the general manager of the company, Huang Jinlong, Zhang Fengliang and Xiang Chongping as the deputy general managers of the company, Lan Xiaolong as the financial director of the company, and Zhu Jianwei as the secretary of the board of directors of the company. The new board of supervisors held its first meeting and elected Chen Tianci as the chairman of the company's tenth board of supervisors. The term of office of the current board of directors, the board of supervisors and the management team is three years. At the
meeting, Chairman Jiang Xiaomeng expressed his gratitude to the majority of shareholders for their long-term support to the work of the company's board of directors and board of supervisors, and expressed his gratitude to the members of the company's tenth board of directors and the ninth board of supervisors for their diligence and dedication. Looking forward to the work of the board of directors, Chairman Jiang Xiaomeng pointed out that the next three years will be crucial to the company's development, the company's new board of directors, board of supervisors, and new management team should lead all employees of the company to seize opportunities and meet challenges, further carry forward the spirit of the peak, work hard, and strive to create a better future for Jianfeng Group. (residual fruit)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31